참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 3-Bromopyridine | HCID 12286 | — |
| 반응물 | tert-Butyl piperazine-1-carboxylate | HCID 143452 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | Tert-butyl 4-(pyridin-3-YL)piperazine-1-carboxylate | HCID 11673373 | 37.96% |
반응 단계
diacetoxypalladium (0.072 g, 0.32 mmol) and RuPhos (0.301 g, 0.64 mmol) were stirred in 1,4-dioxane (11.36 ml) for 10 mins at 50 °C.tert-butyl piperazine-1-carboxylate (0.6 g, 3.22 mmol), 3-bromopyridine (0.310 ml, 3.22 mmol) and sodium tert-butoxide (0.464 g, 4.83 mmol) were added and the reaction mixture was stirred at 100 °C for 64 h. The reaction mixture was filtered through celite. The crude product was purified by flash silica chromatography, elution gradient 20 to 100% EtOAc in heptane. Pure fractions were evaporated to dryness to afford tert-butyl 4-(pyridin-3-yl)piperazine-1-carboxylate (0.322 g, 38.0 %) as a yellow oil which crystallised on standing. This was then combined with EN06111-39-01.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-c9d3e32c4ae3434fab0938e5982b9ebd |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|